Home > Healthcare & Medical Devices > Rheumatoid Arthritis Therapeutics Market

Rheumatoid Arthritis Therapeutics Market Size, COVID-19 Impact Analysis, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2022 – 2028

  • Report ID: GMI4247

Rheumatoid Arthritis Therapeutics Market Size is projected to be impelled significantly from 2022 to 2028 owing to the growing prevalence of arthritis. Factors like the rising acceptance of biopharmaceuticals, surge in the geriatric population worldwide, and presence of well-defined healthcare guidelines in developed nations would foster the demand for RS therapeutics solutions.

Ongoing R&D activities in the business sphere would impel the market dynamics over the foreseeable period. For instance, in 2021, Navidea Biopharmaceuticals launched Phase 3 clinical trial in rheumatoid arthritis. The trial is expected to establish the ability of Tc99m tilmanocept imaging to serve as a nascent stage of the treatment response in RA patients.

The industry expansion is being further supported by the rising patient cognizance pertaining to rheumatic disorders and the introduction of new biopharmaceuticals in the global space.

Based on the drug type, the pharmaceuticals segment including analgesics, NSAIDs, and others would account for notable growth over 2022-2028. Amongst these, non-steroidal anti-inflammatory agents (NSAIDs) are extensively used in the symptomatic management of rheumatic diseases characterized by diverse forms of acute pain and chronic musculoskeletal pain. The major effect of these drugs is to decrease acute inflammation thus reducing the pain and improving the overall function. Studies report that in some cases, lower doses of NSAIDs are effective in RS to decrease inflammation.

In terms of the sales channel, online pharmacy segment is slated to grow exponentially. This can be credited to the growing e-commerce industry and growing preference for online sales of pharmaceuticals during the COVID-19 in wake of the infection spread. The segmental growth is further propelled by the increasing smartphone and internet penetration. In addition, the availability of discounts and multiple products on different platforms would allow consumers to choose from suitable options, enhancing the business space.

Geographically, Europe rheumatoid arthritis therapeutics market is speculated to record notable gains through 2028. The growth in the market would come from increasing prevalence of arthritis in major countries including the United Kingdom and Germany. As per estimates, nearly 1% of the population in the United Kingdom suffers from rheumatoid arthritis. Moreover, expanding healthcare spending and well-developed health infrastructure across these economies, which is largely being supported by the federal governments, would boost the regional market progression in the coming years. Besides, increasing research activities, rising pipeline drugs, and the presence of various pharmaceutical and medical players in the region would further add to the market growth.

Pfizer Inc., Johnson & Johnson, Hoffmann-La Roche AG, AbbVie, Novartis International AG, Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc, and Amgen Inc., amongst others are some of the prominent names functioning in the rheumatoid arthritis therapeutics market. The solution providers are engaging in different organic marketing strategies like mergers and acquisitions, partnerships, product launches, and more to gain a competitive advantage over others.

Analyzing coronavirus impact on rheumatoid arthritis therapeutics market outlook

The overall market was known to be moderately affected by the daunting outbreak of SARS-CoV-2 infection spread worldwide. A decline in production of rheumatoid arthritis therapeutics, including pharmaceutical drugs, due to the unavailability of raw materials and commotion in supply chain, along with a decrease in demand for hospital treatments due to the scare of acquiring infection, have negatively influenced the market share. However, rise in the online sales of rheumatoid arthritis analgesics or pills has resulted in a moderate industry growth.

The rheumatoid arthritis therapeutics market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2017 to 2028 for the following segments:

Market, by Drug Type

  • Pharmaceuticals
    • NSAIDs
    • Analgesics
    • DMARDs
    • Glucocorticoids
  • Biopharmaceuticals
    • Biologics
    • Biosimilars

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
  • Latin America
    • Mexico
    • Brazil
    • Argentina
  • Middle East and Africa
    • South Africa
    • Saudi Arabia


What Information does this report contain?

Historical data coverage: 2017 to 2021; Growth Projections: 2022 to 2028.
Expert analysis: industry, governing, innovation and technological trends; factors impacting development; drawbacks, SWOT.
6-7 year performance forecasts: major segments covering applications, top products and geographies.
Competitive landscape reporting: market leaders and important players, competencies and capacities of these companies in terms of production as well as sustainability and prospects.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Budget constraints? Get in touch with us for special pricing

Request Discount

Our Market Research Reports Include:

  • Market snapshot
  • Market Segmentation
  • Value Chain Analysis
  • Growth Dynamics
  • Potential Market Opportunities
  • Regulatory Overview
  • Technology Evolution
  • Innovation & Sustainability